Spectral Med Financials

EDT Stock  CAD 0.54  0.01  1.82%   
We advise to exercise Spectral Med analysis to find out if markets are presently mispricing the firm. We were able to interpolate and analyze data for thirty-three available drivers for Spectral Med, which can be compared to its competition. The stock experiences a somewhat bearish sentiment, but the market may correct it shortly. Check odds of Spectral Med to be traded at C$0.5238 in 90 days. Key indicators impacting Spectral Med's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio0.440.46
Sufficiently Down
Slightly volatile
  
Understanding current and past Spectral Med Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Spectral Med's financial statements are interrelated, with each one affecting the others. For example, an increase in Spectral Med's assets may result in an increase in income on the income statement.

Spectral Med Stock Summary

Spectral Med competes with Excelsior Mining, Vista Gold, Condor Energies, TeraGo, and Intermap Technologies. Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada. SPECTRAL MEDICAL operates under Diagnostics Research classification in Canada and is traded on Toronto Stock Exchange. It employs 18 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentCanada Stock View All
ExchangeToronto Exchange
ISINCA8475771033
Business Address135 The West
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitespectraldx.com
Phone416 626 3233
CurrencyCAD - Canadian Dollar
You should never invest in Spectral Med without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Spectral Stock, because this is throwing your money away. Analyzing the key information contained in Spectral Med's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Spectral Med Key Financial Ratios

Spectral Med's financial ratios allow both analysts and investors to convert raw data from Spectral Med's financial statements into concise, actionable information that can be used to evaluate the performance of Spectral Med over time and compare it to other companies across industries.

Spectral Med Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets8.2M11.6M12.0M5.2M4.7M4.5M
Other Current Liab980K1.1M4.1M7.5M8.7M9.1M
Net Debt(5.1M)(8.3M)(1.8M)5.6M6.5M6.8M
Retained Earnings(89.7M)(98.5M)(109.7M)(125.4M)(112.9M)(107.2M)
Accounts Payable1.2M444K1.7M1.6M1.4M1.1M
Cash5.8M8.9M8.4M3.0M2.7M2.5M
Net Receivables260K205K1.1M186K167.4K159.0K
Other Current Assets389K875K276K621K558.9K293.1K
Total Liab8.8M7.5M14.5M21.8M25.0M26.3M
Total Current Assets6.8M10.3M10.1M4.1M3.7M3.5M
Short Term Debt85K92K175K385K442.8K420.6K
Intangible Assets246K228K211K193K173.7K165.0K
Inventory348K293K340K366K329.4K474.6K
Common Stock71.9M84.4M87.1M87.1M100.1M68.9M
Net Tangible Assets2.0M(915K)3.9M(2.7M)(2.5M)(2.3M)
Long Term Debt Total667K582K490K6.5M7.5M7.9M
Net Invested Capital(669K)4.1M3.6M(8.6M)(7.7M)(7.4M)
Net Working Capital3.9M8.0M6.1M(6.1M)(5.5M)(5.2M)
Capital Stock71.9M84.4M87.1M87.1M100.1M85.0M

Spectral Med Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense32K28K104K1.3M1.2M1.3M
Total Revenue2.1M2.1M1.7M1.6M1.4M1.4M
Gross Profit1.5M1.2M983K662K595.8K566.0K
Operating Income(9.1M)(8.6M)(9.4M)(11.4M)(13.1M)(13.8M)
Ebit(9.1M)(6.9M)(7.5M)(14.2M)(16.3M)(15.5M)
Ebitda(8.8M)(6.6M)(7.2M)(14.0M)(12.6M)(11.9M)
Net Income(9.0M)(8.7M)(11.3M)(15.7M)(14.1M)(13.4M)
Income Before Tax(9.1M)(8.8M)(9.6M)(15.5M)(14.0M)(13.3M)
Cost Of Revenue628K832K684K936K842.4K1.2M
Net Interest Income(32K)(28K)(104K)(1.3M)(1.2M)(1.1M)

Spectral Med Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash4.4M3.1M(476K)(5.5M)(4.9M)(4.7M)
Free Cash Flow(639K)(9.2M)(10.0M)(10.9M)(12.5M)(13.2M)
Depreciation304K294K272K218K196.2K186.4K
Other Non Cash Items32K28K(806K)3.6M4.2M4.4M
Capital Expenditures315K483K33K185K166.5K158.2K
Net Income(9.1M)(8.8M)(11.3M)(15.7M)(14.1M)(13.4M)
End Period Cash Flow5.8M8.9M8.4M3.0M2.7M2.5M
Change To Inventory(72K)(51K)(47K)(26K)(23.4K)(24.6K)
Investments(297K)(325K)(33K)(185K)(166.5K)(158.2K)
Change To Netincome722K1.1M1.5M391K449.7K675.4K

Spectral Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Spectral Med's current stock value. Our valuation model uses many indicators to compare Spectral Med value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Spectral Med competition to find correlations between indicators driving Spectral Med's intrinsic value. More Info.
Spectral Med is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . At this time, Spectral Med's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Spectral Med by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Spectral Med's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Spectral Med Systematic Risk

Spectral Med's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Spectral Med volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Spectral Med correlated with the market. If Beta is less than 0 Spectral Med generally moves in the opposite direction as compared to the market. If Spectral Med Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Spectral Med is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Spectral Med is generally in the same direction as the market. If Beta > 1 Spectral Med moves generally in the same direction as, but more than the movement of the benchmark.

Spectral Med Total Assets Over Time

Today, most investors in Spectral Med Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Spectral Med's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Spectral Med growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.24)

At this time, Spectral Med's Price Earnings To Growth Ratio is very stable compared to the past year.

Spectral Med January 4, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Spectral Med help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Spectral Med. We use our internally-developed statistical techniques to arrive at the intrinsic value of Spectral Med based on widely used predictive technical indicators. In general, we focus on analyzing Spectral Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Spectral Med's daily price indicators and compare them against related drivers.

Other Information on Investing in Spectral Stock

Spectral Med financial ratios help investors to determine whether Spectral Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spectral with respect to the benefits of owning Spectral Med security.